Lisata clinches rare disease status for osteosarcoma drug
Lisata Therapeutics announced a rare pediatric drug designation for LSTA1, which is being studied in several early to mid-stage clinical studies.
Lisata Therapeutics announced a rare pediatric drug designation for LSTA1, which is being studied in several early to mid-stage clinical studies.
What's Your Reaction?
